Psychostimulant drug co-ingestion in non-fatal opioid overdose
Drug and Alcohol Dependence Reports · 2024-03 · 10 · 100223
DOI: 10.1016/j.dadr.2024.100223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Alcohol Dependence Reports, 2024-03. Verfasst von Siri Shastry und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, National Institute on Drug Abuse.
Abstract (Originalsprache)
Introduction
In 2019, there were over 16,000 deaths from psychostimulant overdose with 53.5% also involving an opioid. Given the substantial mortality stemming from opioid and psychostimulant co-exposure, evaluation of clinical management in this population is critical but remains understudied. This study aims to characterize and compare clinical management and outcomes in emergency department (ED) overdose patients with analytically confirmed exposure to both opioids and psychostimulants with those exposed to opioids alone.
Methods
This was a secondary analysis of a prospective consecutive cohort of ED patients age 18+ with opioid overdose at 9 hospital sites from September 21, 2020 to August 17, 2021. Toxicologic analysis was performed using liquid chromatography quadrupole time-of-flight mass spectrometry. Patients were divided into opioid-only (OO) and opioid plus psychostimulants (OS) groups. The primary outcome was total naloxone bolus dose administered. Secondary outcomes included endotracheal intubation, cardiac arrest, troponin elevation, and abnormal presenting vital signs. We employed t-tests, chi-squared analyses and multivariable regression models to compare outcomes between OO and OS groups.
Results
Of 378 enrollees with confirmed opioid overdose, 207 (54.8%) had psychostimulants present. OO patients were significantly older (mean 45.2 versus 40.6 years, p < 0.01). OS patients had significantly higher total naloxone requirements (mean total dose 2.79 mg versus 2.12 mg, p = 0.009). There were no significant differences in secondary outcomes.
Conclusion
Approximately half of ED patients with confirmed opioid exposures were also positive for psychostimulants. Patients in the OS group required significantly higher naloxone doses, suggesting potential greater overdose severity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- American College of Medical Toxicology, Phoenix, AZ, USA.
- Department of Emergency Medicine, Baylor University Medical Center, Dallas, TX, USA.
- University of Colorado School of Medicine, Aurora, CO, USA.
- Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Förderung
- National Institutes of Health
- National Institute on Drug Abuse
Zitieren
APA
Shastry, S., Shulman, J., Aldy, K., Brent, J., Wax, P., Manini, A. F., & Toxicology Investigators Consortium Fentalog Study Group (2024). Psychostimulant drug co-ingestion in non-fatal opioid overdose. Drug and Alcohol Dependence Reports, 10, 100223. https://doi.org/10.1016/j.dadr.2024.100223
Vancouver
Shastry S, Shulman J, Aldy K, Brent J, Wax P, Manini AF, et al. Psychostimulant drug co-ingestion in non-fatal opioid overdose. Drug and Alcohol Dependence Reports. 2024;10:100223. doi:10.1016/j.dadr.2024.100223
BibTeX
@article{Shastry2024,
author = {Shastry, Siri and Shulman, Joshua and Aldy, Kim and Brent, Jeffrey and Wax, Paul and Manini, Alex F and Toxicology Investigators Consortium Fentalog Study Group, Toxicology Investigators Consortium Fentalog Study Group},
title = {Psychostimulant drug co-ingestion in non-fatal opioid overdose},
journal = {Drug and Alcohol Dependence Reports},
year = {2024},
volume = {10},
pages = {100223},
doi = {10.1016/j.dadr.2024.100223}
}
EUVIMED